Printed From:

When maximally tolerated statins and diet aren’t enough to get patients with clinical ASCVD or HeFH to their LDL-C goal…

HIGH LDL-C & PRIOR CV EVENT*? TIME TO ACT

PRALUENT® (alirocumab) is the only PCSK9i with 2 powerful levels of efficacy to help you choose the appropriate LDL-C reduction for each patient1

DOSING INFORMATION

  • The recommended starting dose of PRALUENT is 75 mg once every 2 weeks administered subcutaneously or alternatively 300 mg once every 4 weeks (monthly) for patients who prefer less frequent dosing. The majority of patients achieve sufficient LDL-C reduction with the 75-mg dosage. If the LDL-C response is inadequate, the dosage may be adjusted to the maximum dosage of 150 mg administered every 2 weeks

ASCVD = atherosclerotic cardiovascular disease;

CV = cardiovascular;

HeFH = heterozygous familial hypercholesterolemia;

LDL-C = low-density lipoprotein cholesterol.

Reference:

  1. PRALUENT® (alirocumab) Prescribing Information. Sanofi and Regeneron Pharmaceuticals.